Online Course

2018 CARE MOC Session 3 - OA and Gout/Pseudogout

Date:

Expires Sep 30, 2019

Program Information

CME: 4     MOC: 4

Assess your rheumatology medical knowledge and enhance your patient care. With 2018 CARE MOC Session 3 - OA and Gout/Pseudogout you receive:

  • 12 case-based, multiple-choice questions with in-depth answer rationales
  • 4 AMA PRA Category 1 Credits™ and 4 ABIM MOC points with a passing score of 70% or higher

This online activity is for 2018 ACR/ARP Annual Meeting attendees only.

Target Audience
This course is designed for rheumatologists, physicians, and healthcare providers who care for patients with rheumatic diseases, and those interested or engaged in rheumatology research.

Learning Objectives
Upon completion of this program, participants should be able to:

  • Implement various management options in OA
  • Recognize factors that contribute to OA pathogenesis and symptoms
  • Evaluate clinical features associated with gout and pseudogout
  • Assess available evidence supporting current therapeutic options in the treatment of pseudogout and gout
  • Evaluate epidemiologic risk factors related to the development of gout

Registration Fees

Free for 2018 ACR/ARP Annual Meeting attendees.

CME and MOC Information

Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The ACR designates this online activity for a maximum of 4 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

MOC Statement
Successful completion of this CME activity enables the participant to earn up to 4 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claim MOC Points
See instructions on how to claim MOC points

Faculty and Disclosures

ACR Disclosure Statement
The ACR is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. Educational activities provided by the ACR must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias.

Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience any financial or other relationship(s) including, but not limited to:

  1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
  2. Research grants
  3. Employment (full or part-time)
  4. Ownership or partnership
  5. Consulting fees or other remuneration (payment)
  6. Non-remunerative positions of influence such as officer, board member, trustee, or public spokesperson
  7. Receipt of royalties
  8. Speakers' bureau
  9. Other

The faculty reported the following disclosures.

  • Moderator: Juliet Aizer, MD, MPH - No relevant financial relationships to disclose
  • Speaker: Tuhina Neogi, MD, PhD - No relevant financial relationships to disclose
  • Speaker: Allan Gelber, MD, PhD, MPH - No relevant financial relationships to disclose
  • Question Author: Arundathi Jayatilleke, MD - No relevant financial relationships to disclose
  • Question Author: Amanda Sammut, MD - No relevant financial relationships to disclose

Additional Program Information

2018 Annual Meeting Live Session: October 22, 12:30 PM - 2:00 PM
Moderator: Juliet Aizer, MD, MPH - Hospital for Special Surgery
Speakers: Allan Gelber, MD, PhD, MPH - Johns Hopkins University and Tuhina Neogi, MD, PhD - Boston University
Question Authors: Arundathi Jayatilleke, MD - Drexel University and Amanda Sammut, MD - Harlem Hospital Center

About the Speaker
Dr. Neogi is a rheumatologist and epidemiologist whose research has focused primarily on risk factors for knee osteoarthritis and gout, pain mechanisms in knee osteoarthritis, as well as methodologic issues of relevance for rheumatic diseases. She has had continuous peer-reviewed foundation and NIH funding since 2003, and has over 170 peer-reviewed publications to date. Dr. Neogi is the most recent past chair of the FDA Arthritis Advisory Committee, serves on the boards two international societies: Osteoarthritis Research Society International (OARSI) and Gout, Hyperuricemia, and Crystal-Associated Diseases Network (G-CAN); and on committees for the American College of Rheumatology (ACR) and International Association for the Study Pain (IASP), among others. Her work has been recognized with the prestigious 2014 ACR Henry Kunkel Young Investigator Award for outstanding and promising independent contributions to rheumatology research (awarded to no more than one clinical researcher and/or one basic science researcher each year). She has also engaged in developing new classification criteria for a number of rheumatic diseases. In addition to research, clinical work, and teaching, one of her key roles is to mentor trainees and junior faculty in musculoskeletal disease-related research. To that end, she was awarded the 2016 Robert Dawson Evans Research Mentoring Award. She is also leading the new CTSI Research Career Support Program initiative, PRIME (Pathways to Research Independence and Mentoring Excellence), which aims to support early career mentored researchers to successfully transition to becoming independent researchers.

Dr. Neogi’s expertise includes:

  • Osteoarthritis: epidemiology, risk factors, mechanisms of osteoarthritis-related pain, the role of bone in the pathophysiology of osteoarthritis
  • Gout: epidemiology, risk factors and triggers for gout attacks, management of gout, consequences of gout and hyperuricemia
  • Classification criteria and outcome measures in rheumatic diseases
  • Novel methodology to address challenging epidemiologic issues

Contact Info / Inquiries

education@rheumatology.org
404-633-3777, ext. 381